REVIEW

Recent advances in understanding Epstein-Barr virus [version 1; peer review: 4 approved]

Brent A. Stanfield, Micah A. Luftig

Department of Molecular Genetics and Microbiology, Duke Center for Virology, Duke University Medical Center, Durham, NC, USA

Abstract

Epstein-Barr virus (EBV) is a common human herpes virus known to infect the majority of the world population. Infection with EBV is often asymptomatic but can manifest in a range of pathologies from infectious mononucleosis to severe cancers of epithelial and lymphocytic origin. Indeed, in the past decade, EBV has been linked to nearly 10% of all gastric cancers. Furthermore, recent advances in high-throughput next-generation sequencing and the development of humanized mice, which effectively model EBV pathogenesis, have led to a wealth of knowledge pertaining to strain variation and host-pathogen interaction. This review highlights some recent advances in our understanding of EBV biology, focusing on new findings on the early events of infection, the role EBV plays in gastric cancer, new strain variation, and humanized mouse models of EBV infection.

Keywords

EBV, Herpesvirus, Herpes simplex virus, gastric cancer
Introduction

Epstein-Barr virus (EBV), also known as human herpes virus 4, is a gamma-herpes virus that infects the majority of the world’s population. Initial infection with EBV is often asymptomatic but can also manifest as infectious mononucleosis. Following acute lytic replication in epithelial cells, EBV infects B cells where a distinct set of latency-associated genes and transcripts are expressed. EBV was first identified in 1964 from cultured tumor cells derived from a patient with Burkitt’s lymphoma (BL). Early studies have demonstrated EBV’s ability to transform resting human B cells into lymphoblastoid cell lines (LCLs), further supporting the oncogenic potential of this virus. Since then, EBV infection has been associated with a number of different malignancies of both lymphoid and epithelial origin and accounts for 1.8% of all cancer-related deaths worldwide.

In vivo, EBV infection begins in the oral mucosa. Replication in epithelial cells is typically lytic; however, latent infection of epithelial cells can result in nasopharyngeal carcinoma or gastric cancer (as discussed in more detail later). After replication in the epithelia, virus is primed for entry into B cells, where a transient growth program is thought to mimic a germinal center reaction, ultimately promoting maturation of the infected cell into the peripheral memory B-cell compartment. Advances in next-generation sequencing and the development of humanized mice have led to better ways to identify and understand the natural strain variation that occurs with EBV. New strain variations, particularly with mutations in latency-associated genes, have been identified in various malignancies. Harnessing these new humanized mice enables studies modeling latent infection and pathogenesis of host-restricted pathogens like HIV and EBV. This review will focus on the recent advances in EBV biology and primarily on understanding events in early B-cell infection, the role of EBV in gastric cancer, the breadth of EBV strain variation revealed by next-generation sequencing, and recent discoveries made using humanized mice.

Early events

Initial events of infection

EBV entry into epithelial cells occurs by direct fusion of the viral envelope with the cell plasma membrane; however, entry into B cells requires the virus to be endocytosed before membrane fusion to escape the endosome. B-cell entry requires five viral glycoproteins: gp350/220 allows for attachment by binding to CD21, gp42 binds to major histocompatibility complex (MHC) class II to initiate entry, and the core herpesvirus fusion machinery consisting of gB and the heterodimer gH/gL. Interaction of gp350/220 with the cell surface molecule CD21 results in the alteration of major signaling pathways believed to prime the cell to stable latent EBV infection. In particular, specific transcriptional profiles are involved in the evasion of apoptosis and there is evidence that EBV/CD21 binding alters the expression of specific histone transcripts from clusters 1 and 2 (H2AFC, H2AFM, H2BF, H2BFG, H2BI, H3FA, H3FB, H3FL, H4FL, H4FK, H4FI, H4FK, H4F2, H1F3, and H1F4) (Figure 1).

Upon entry into B cells, the virion is endocytosed and is released into the cytoplasm following fusion of the virion membrane with endosomal membrane. This process releases the viral tegument proteins into the host cell. One such tegument protein, BNRF1, binds the cellular protein Daxx and disrupts the Daxx-ATRX complex. This complex is known to suppress transcription through histone methylation. Upon deposition into the nucleus, the viral DNA is associated with cellular histones. Daxx-ATRX might normally support methylation of this new EBV chromatin to suppress transcription of viral genes. However, BNRF1 disruption of the Daxx-ATRX complex allows early viral latent gene expression (Figure 1).

Packaged, virally encoded RNA is also released upon fusion of the virion membrane with endosomal membrane. In particular, BZLF1 transcripts have been shown to be packaged into viral particles and are translated immediately upon release into the infected cell. These immediately translated proteins then function to transactivate viral promoters initiating the pre-latent phase of EBV infection. EBV also counters T-cell responses through the delivery of BNLF2a mRNA and non-coding EBV-encoded RNA transcripts that induce cellular cytokine synthesis. EBV is known to encode at least 44 microRNAs (miRNAs). Though many of the miRNAs have no known function, it has recently been shown that these virally encoded miRNAs function in immune evasion by specifically suppressing the release of interleukin-12 (IL-12), disrupting CD4+ T-cell differentiation into type 1 T helper (Th1) cells, and reducing antigen presentation to CD4+ and CD8+ T cells. These miRNAs function by interfering with peptide processing, by directly targeting the TAP2 subunit, and by disrupting antigen presentation on MHC-II and MHC-I molecules.

Pre-latent gene expression

Pre-latent gene expression occurs immediately upon deposition of the viral genome into the nucleus of newly infected B cells. Promiscuous expression of both lytic and latent genes occurs at this time with the majority of infected B cells initially expressing EBV immediate-early genes. Others have shown that BZLF1, the major transcriptional activator of lytic gene expression, is expressed as early as 1.5 hours post infection in the absence of protein expression, implicating BZLF1 as an immediate-early gene being expressed immediately following B-cell infection. This initial burst of lytic gene expression could be essential to the production of progeny virus competent for infecting new B cells, or immediate expression of lytic genes could be essential for the survival of latently infected B cells through inactivation of p53. However, it is important to note that during this pre-latent phase, genes essential for DNA replication and structural proteins of the virion are not readily detectable.

EBV encodes two bcl-2 proteins: BHRF1 and BALF1. Viral mutants lacking both bcl-2 proteins are unable to initiate proliferation and die from immediate apoptosis. Peak expression of these transcripts is detected at 24 hours post infection, implicating BHRF1 and BALF1 in the initial events prior to cell proliferation. Also, it has recently been shown that BHRF1 is constitutively expressed...
as a latent protein in BamHI W promoter (Wp)-restricted BL cell lines and LCLs\(^2\). These findings implicate BHRF1 and BALF1 proteins as playing an important role in the evasion of apoptosis during latency; however, virally encoded miRNAs also cluster at the \(BHRF1\) locus. Following induction of viral replication in latency I restricted Akata cells, these miRNAs are detectable at 24 hours post stimulation and have been shown to drive proliferation and aid in the evasion of apoptosis\(^22\)–\(^24\).

Hyper-proliferation
Following the pre-latent phase, the initial Epstein-Barr nuclear antigen (EBNA) latency promoter, Wp, is active promoting expression of \(EBNA-LP\) and \(EBNA2\). Subsequently, these proteins transactivate the viral C promoter, Cp, to initiate expression of the EBNA3s and EBNA1 along with their own transcripts to high levels. This EBNA-only gene expression state is associated with a period of rapid proliferation with the first three or four divisions occurring once every 8 to 12 hours\(^2\). This period lasting approximately the first 2 weeks following resting B-cell infection is termed latency II\(^b\)\(^26\)–\(^27\). At this time, the virus expresses all of the EBNA proteins and minimally expresses latent membrane proteins (LMPs) 1, 2A, and 2B\(^26\). LMP1 is expressed as early as 2 days post infection; however, during this period, inhibition of early nuclear factor-kappa B (NF\(\kappa\)B) activation does not affect transformation, supporting the distinction of this latency phase from the LCL state, which requires LMP1-mediated NF\(\kappa\)B activity for survival\(^26\).

As a consequence of this rapid proliferation, EBV-infected B cells are susceptible to growth arrest induced by hyper-proliferation-associated DNA damage responses\(^26\)–\(^28\). Cells then transition from a period of rapid proliferation and high Myc activity to the steady-state proliferation (about 24 hours per cycle) observed in LCLs with lower Myc and high NF\(\kappa\)B activity\(^26\)–\(^28\). The high Myc/low NF\(\kappa\)B state that occurs during latency II\(b\)
might play a role in immune evasion as elevated Myc and low NFκB as observed in BL have been implicated in downregulation of MHC class I and II (MHC-I and MHC-II) and avoidance of T-cell recognition and killing\textsuperscript{29,30}.

**Epstein-Barr virus infection in gastric cancer**

Viral entry into epithelial cells is primarily mediated by three CD21-independent mechanisms. First, EBV can enter into epithelial cells by close membrane-to-membrane contact of EBV-infected lymphocytes to uninfected epithelial cells. Second, cell-free virus can enter polarized epithelial cells through their basolateral membranes which is mediated in part by interaction between BMRF2 and betal and alpha5beta1 integrins. The third mechanism is by lateral spread through the epithelium from infected to uninfected epithelial cells\textsuperscript{31}. EBV-associated gastric carcinomas (EBVaGCs) are epithelial in origin and make up approximately 9\% of all gastric carcinomas worldwide\textsuperscript{32}. EBVaGCs characteristically acquire mutations within the cellular PIK3CA gene and display extreme cellular DNA hyper-methylation. Specifically, mutations in PIK3CA identified in intestinal-type gastric cancers were associated with an increased tumor incidence in the lower third of the stomach compared with those without \textsuperscript{33}. Also, PIK3CA mutations in diffuse-type gastric cancer were associated with an increased tumor incidence in the upper third of the stomach and an increased association with hematogenous metastasis. Tumors identified with PIK3CA mutation in the middle third of the stomach had an increased association with EBV infection and increased peritoneal recurrence; however, PIK3CA mutations did not demonstrate a significant effect on patient outcomes.

EBVaGCs are also known to have increased expression of JAK2, programmed death ligand 1 (PD-L1), and PD-L2\textsuperscript{34}. PD-L1 is known to interact with programmed death receptor 1 found on the surface of T cells. This interaction causes the inhibition of T-cell proliferation, cytokine secretion, and cytotoxic activity (reviewed in 35). Also, EBVaGCs have been shown to express BNLF2a, which functions in immune evasion by inhibiting the transporter associated with antigen-processing transport of antigentic peptides. Though this transcript is typically associated with lytic replication, in gastric cancers it is expressed latently and has the potential to protect the infected cell from immunosurveillance\textsuperscript{36}. Despite the immunologically evasive nature of EBVaGC, patients with diagnosed EBVaGC had longer survival post diagnosis as opposed to EBV-negative gastric carcinoma\textsuperscript{37}.

Infection of an EBV-negative GC cell line (AGS) with Akata EBV results in robust expression of virally encoded BART miRNAs with minimal protein expression\textsuperscript{38}. Importantly, these infected AGS cells displayed a more transformed phenotype than their uninfected counterparts. The prototypical transforming EBV strain, B95-8, readily infects and immortalizes human B cells. However, this virus is deleted for most of the BART miRNAs, and infection of B cells with viral variants encoding these miRNAs results in minimal BART expression\textsuperscript{39,40}. This tissue-specific BART expression suggests that these miRNAs are likely to play a significant role in the transformed growth properties of EBVaGC.

Recently, it has been shown that CRISPR/Cas9-mediated cleavage for bacterial artificial chromosome (BAC) insertion into EBV episomal DNA in gastric carcinoma (GC) cell lines has facilitated the cloning of these viral genomes with unprecedented efficiency\textsuperscript{41}. Subsequent infection of epithelial cells with the BAC clone reconstituted viruses induced resistance to oncogene-induced cell death, providing important clues concerning EBV-mediated epithelial carcinogenesis. Establishing this new state-of-the-art technique will enable future investigation into new strain variations and their relationship with EBV-associated disease.

**Epstein-Barr virus strain variation**

Recent advances in next-generation whole genome sequencing (NGS) have changed the landscape surrounding the analysis of EBV-type differences. Historically, the major distinction in EBV strains has been the delineation of type 1/type 2. Currently, the largest distinguishing factors between EBV type 1 and type 2 rely on differences observed in the EBNA2 and EBNA3A, EBNA3B, and EBNA3C genes. Indeed, it has been shown that a single amino acid change in the transactivation domain of EBV-2 EBNA2 (S442D) can drastically alter EBV-2 B-cell transformation efficacy similar to that observed with EBV-1 and increase induction of LMP1 expression with a higher affinity for the LMP1 promoter\textsuperscript{42}. However, a number of other factors may contribute to the underlying strain variation, including immunological pressures, skewed cell tropism, and geographic isolation\textsuperscript{43}. Indeed, a recently described strain of EBV derived from a nasopharyngeal carcinoma case, M81, displays high epithelial tropism and also contains a polymorphism in the promoter of the lytic transactivator BZLF1 leading to elevated lytic replication\textsuperscript{44}.

It has been proposed that the prevalence of MHC haplotypes within specific geographic regions induces immunological pressures that can contribute to strain variation within immunologically dominant epitopes of particularly immunogenic proteins\textsuperscript{45}. However, recent sequence analyses demonstrate that the large numbers of non-synonymous mutations observed in the EBNA3 proteins are outside of known cytotoxic T-cell epitopes. More work is needed to identify alternative cytotoxic T lymphocyte (CTL) epitopes within the EBNA3s to explain this variation, or alternatively another selective pressured could be driving this variation perhaps regarding EBNA3 function\textsuperscript{44}. For example, a recent study found that EBNA3B, an immunodominant latency protein, actually serves as a tumor suppressor and can be found deleted in EBV strains associated with diffuse large B-cell lymphomas (DLBCLs)\textsuperscript{46}.

Recently, a provocative study implicated EBV-2 as having unique cell tropism skewing toward CD8+ T cells\textsuperscript{47}. EBV has also been commonly detected in non-B cells in the blood of patients with EBV-positive lymphoproliferative disorder (LPD), including patients with HIV, post-transplant, anaplastic anemia, chronic active EBV (CA-EBV), and others\textsuperscript{48,49}. While CA-EBV patients often had EBV+ T cells in the blood, other EBV+ LPD patients contained EBV in monocytes as well as non-B, non-T, non-monocyte cell types based on surface staining\textsuperscript{47}. Although this population is
certainly skewed from the norm with elevated viral loads and altered EBV immune responses, these findings suggest that EBV infection of T cells may be clinically relevant in some instances. Indeed, the detection of EBV in natural killer (NK)/T lymphomas and a high percentage of T cells in EBV-associated hemophagocytic lymphohistiocytosis (HLH) suggest that lack of control of EBV infection might be associated with a broadening of cellular tropism. Interestingly, cases of CA-EBV are most commonly reported as being of T and NK cell origin in Asia and almost entirely B-cell origin in the United States. Information gained through NGS studies coupled with further virus-host interaction work in vitro and clinical observation will lead to a greater understanding of how different EBV strains might achieve these drastic differences in cellular tropism and maintenance of latency in various cell types.

**Humanized mouse models of Epstein-Barr virus infection**

EBV infection had been restricted to *in vitro* systems until the breakthrough of the scid-hu PBL mouse. Scid-hu PBL mice are based on the C.B-17 severe combined immunodeficient (SCID) mouse, which lack both B and T cells. These mice are injected with human peripheral blood mononuclear cells and, after infection with EBV, effectively model the LPD observed in immunocompromised humans (reviewed in [55]). However, these mice have several drawbacks, including frequently observed graft-versus-host disease caused by the human T cells attacking mouse tissue, the transient nature of the engrafted human immune system, and a relatively low level of engraftment. Most importantly, these mice are unable to mount adaptive immune responses with their engrafted immune systems.

In order to overcome the obstacles of the scid-hu PBL mouse model, a new suite of humanized mice was generated by transplantation of non-obese diabetic/SCID (NOD/SCID) animals with hematopoietic stem cells. These NOD/SCID mice have a complete null mutation of the common IL-2 cytokine receptor gamma chain—NOD/LtSz-scid/IL-2 receptor gamma null (NSG), NOD/Shi-scid/IL-2 receptor gamma null (NOG)—and, once transplanted, display a humanized immune system that persists for more than 24 weeks post transplant (reviewed in [56]). In this model, the CD34+ hematopoietic stem cells are able to differentiate into various mature blood cells, including myelomonocytes, dendritic cells, erythrocytes, platelets, and lymphocytes. B cells undergo normal class switching, produce normal immunoglobulins, and even infiltrate into mucosal tissues in these mice. However, it is important to note that circulating IgG is approximately 1,000 times lower than that observed in immunocompetent humans and that infiltration into mucosal tissues has been demonstrated to be severely attenuated. Differentiated T cells display human MHC-I/HLA-restricted cytotoxic functions: a vast improvement over scid-hu PBL mice. The introduction of the human HLA A2 allele into NSG mice transplanted with CD34+ hematopoietic stem cells (NSG-HLA-A2) resulted in mice capable of reproducing adaptive immune responses known to occur after EBV infection of HLA A2-expressing individuals. These NSG-HLA-A2 mice have been used to demonstrate the essential contribution of NK cells in controlling EBV infection with NK depletion resulting in the development of disseminated EBV+ lymphomas. Further still, the BLT-NOD mice were developed by transplantation of autologous human hematopoietic fetal liver CD34+ cells into NOD/SCID mice previously implanted with human fetal thymic and liver tissues. This resulted in long-term, systemic human T-cell homeostasis capable of mounting anti-EBV MHC-I and MHC-II restricted adaptive immune responses. Given the vast improvements in small animal models of EBV infection, we now have the tools to study post-transplant LPD in the context of a human immune system, adaptive immune responses to EBV infection, and an experimental model to understand the *in vivo* effects of strain variation and other important biological questions.

**Concluding remarks**

The recent advances described in this review address many of the key questions facing the EBV field today. With the advent of NGS and the development of humanized mice to better model EBV disease *in vivo*, we now have the tools to better understand the effects of strain variation on the development of EBV-associated diseases. Future research will benefit from further refinement of the humanized mouse models to better model the full spectrum of the human immune response to EBV infection with the aim of developing effective EBV-specific prophylactics and therapeutics. Further studies of the early period after B-cell infection and its contribution to tumorigenesis and immune evasion will be important to study in the humanized mouse. Finally,
the role of EBV in epithelial malignancies and other diseases outside of the B-cell compartment is ripe for study in this post-genomic era of EBV biology.

**Competing interests**
The authors declare that they have no competing interests.

**Grant information**
This work received funding support from the National Cancer Institute (grant R01CA140337) and the National Institute of Dental and Craniofacial Research (grant R01DE025994).

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*


Open Peer Review

Current Peer Review Status: ✔ ✔ ✔ ✔ ✔

Editorial Note on the Review Process
F1000 Faculty Reviews are written by members of the prestigious F1000 Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1 Bo Zhao
   - - - - - USA
   Competing Interests: No competing interests were disclosed.

2 Richard M. Longnecker
   Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
   Competing Interests: No competing interests were disclosed.

3 Alan K Chiang
   - - - - - USA
   Competing Interests: No competing interests were disclosed.

4 Christian Münz
   Department of Viral Immunology, Institute of Experimental Immunology, University of Zürich, Zurich, Switzerland
   Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com